Company intelligence / Profile preview

Amphista Therapeutics

Cambridge / Granta Park, England/Cambridgeshire, United Kingdomamphista.com ↗

Ownership: Private
Employees: ~125
Development stage: Preclinical

Overview

Amphista has demonstrated differentiated mechanisms of action for its TPD assets in preclinical studies, including novel approaches to BRD9 degradation. The company has achieved discovery milestones in partnerships with major pharma companies but has not yet reported human clinical trial results.

Therapeutic areas: OncologyImmunologyNeurology
Modalities: Targeted protein degradation (TPD) using small molecule bifunctional "targeted glues" and degraders
Industry: Biotech

Drug pipeline

2 assets

AMX-883

1 more asset in the full pipeline.

Request access →

Partnerships

Bristol Myers Squibb ($30M upfront + up to $1.25B milestones)Merck Healthcare (€39M upfront/R&D + up to €893.5M milestones)

Beyond the preview

Go deeper on Amphista Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amphista Therapeutics.

Explore the full profile